In Case You Missed It: NBA in Baltimore

Factor VII timeline

Medical ResearchMedicineTrials and ArbitrationColleges and UniversitiesArmed Forces

• March 1999 -- The U.S. Food and Drug Administration approves Recombinant Activated Factor VII for treating bleeding in patients with rare forms of hemophilia.

• May 1999 -- U.S. Army Col. John B. Holcomb and Israeli Dr. Uri Martinowitz discuss the use of Factor VII in battlefield trauma at a medical conference in Israel.

• June 1999 -- Martinowitz injects two doses of Factor VII into a 19-year-old Israeli soldier who was shot through the abdomen with a high-powered rifle, the first reported use of the drug in a non-hemophiliac. The bleeding "stopped immediately," according to Martinowitz.

• March 2001 -- Holcomb and a group of other American doctors meet in Chicago to begin planning a clinical trial to test Factor VII in trauma patients. The FDA later orders a stop to the effort, citing a lack of evidence that the drug is safe.

• Early 2002 -- An international clinical trial, based at a trauma center in South Africa, begins using the same test proposed by the American doctors.

• February 2004 -- The U.S. Army establishes Factor VII as a standard treatment for wounded soldiers in Iraq, based on unpublished results from the South African study suggesting that the drug is no more dangerous than a placebo.

• February 2005 -- A Columbia University study published in the New England Journal of Medicine suggests that Factor VII is an effective treatment for bleeding in the brain, but with a rate of clot-related complications as high as 10 percent.

• July 2005 -- Results of the 277-patient South Africa trial are published, showing no increased complication rate but also showing little effect on treating patients with penetrating injuries.

• September 2005 -- Researchers at the University of Colorado publish results of a 315-patient survey of Factor VII use in American hospitals, showing a 9.8 percent complication rate caused mostly by "undesirable clotting."

• December 2005 -- The FDA issues a "safety alert" about clots in Factor VII patients without hemophilia, and the drug's label is revised to warn of the potential for heart attacks and strokes.

• January 2006 -- Researchers for the FDA publish a paper in the Journal of the American Medical Association attributing 43 deaths to clots after injections of Factor VII, mostly in patients without hemophilia.

• April 2006 -- Novo Nordisk withdraws a request in Europe for approval of Factor VII to treat bleeding in the brain, after regulators there express concerns about "excessive clotting."

• September 2006 -- Doctors at the R Adams Cowley Shock Trauma Center in Baltimore present results of a study showing an 8.7 percent rate of clot-related complications in their patients given Factor VII, including 12 deaths attributed, in part, to the drug.

Copyright © 2014, The Baltimore Sun
Related Content
Medical ResearchMedicineTrials and ArbitrationColleges and UniversitiesArmed Forces
  • Sun coverage: Factor VII
    Sun coverage: Factor VII

    A warning from the U.S. Food and Drug Administration, along with several published research papers, has linked Factor VII to several types of blood clots that can form in a patient's veins or arteries.

  • Oscar Pistorius sentenced 5 years for Steenkamp killing
    Oscar Pistorius sentenced 5 years for Steenkamp killing

    A South African judge on Tuesday sentenced Olympic and Paralympic track star Oscar Pistorius to five years in prison for the negligent killing of his girlfriend Reeva Steenkamp on Valentine's Day last year.